Synonym: 4-[2-[4-[(11R)-3,10-Dibromo-8-chloro-6,11-dihydro-5Hbenzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-1-piperidinecarboxamide; SCH-66336; SCH66336
CAS Number: 193275-84-2
Empirical Formula (Hill Notation): C27H31Br2ClN4O2
Molecular Weight: 638.82
MDL Number: MFCD06795138
Linear Formula: C27H31Br2ClN4O2
Product Type: Chemical
assay |
≥98% (HPLC) |
color |
white to beige |
form |
powder |
InChI |
1S/C27H31Br2ClN4O2/c28-20-12-19-2-1-18-13-21(30)14-22(29)24(18)25(26(19)32-15-20)17-5-9-33(10-6-17)23(35)11-16-3-7-34(8-4-16)27(31)36/h12-17,25H,1-11H2,(H2,31,36)/t25-/m1/s1 |
InChI key |
DHMTURDWPRKSOA-RUZDIDTESA-N |
Quality Level |
100 |
SMILES string |
O=C(N)N(CC1)CCC1CC(N2CCC([C@H]3C(N=CC(Br)=C4)=C4CCC5=C3C(Br)=CC(Cl)=C5)CC2)=O |
solubility |
DMSO: 5 mg/mL, clear (warmed) |
storage temp. |
−20°C |
Biochem/physiol Actions: |
Lonafarnib is a potent inhibitor of farnesyltransferase, an enzyme responsible for a post-translational modification of proteins (including Ras) that gives a protein sufficient hydrophobicity to translocate to the plasma membrane. Farnesylation regulates signaling cascades controlling cell survival, proliferation and differentiation, so variety of possible uses is not surprising a post-translational modification of proteins (including Ras) that gives a protein sufficient hydrophobicity to translocate to the plasma membrane. Lonafarnib has been studies for possible treatment of progeria, various cancers, and hepatitis D. |
Biochem/physiol Actions: |
Lonafarnib prevents the post-translational lipid modification of H-Ras and other farnesylated proteins. Lonafarnib treatment results in microtubule bundling, increased microtubule acetylation and stabilization and suppression of microtubule dynamics. |
General description: |
Lonafarnib (SCH66336) is a farnesyl transferase inhibitor (FTI). K- and N-Ras are substrates of farnesyl transferase. |
Packaging: |
5, 25 mg in glass bottle |
Purity |
≥98% (HPLC) |
Storage Temp. |
−20°C |
UNSPSC |
12352200 |